Egle Therapeutics announces positive Phase 1 data for EGL-003
EGL-003 was well tolerated and produced selective, dose-dependent Treg expansion in 24 healthy volunteers, supporting a MAD atopic dermatitis study planned for Q4 2026.
See the latest news and media coverage for Egle. We track all announcements, press releases, and industry mentions in real time, all in one place.
Clinical-stage biotechnology company developing regulatory T cell-targeted medicines
egle-tx.comLast updated
In short: Egle reported positive EGL-003 Phase 1 data and won €8 million in EU funding for an EGL-001 cancer trial.
EGL-003 was well tolerated and produced selective, dose-dependent Treg expansion in 24 healthy volunteers, supporting a MAD atopic dermatitis study planned for Q4 2026.
It shares safety and pharmacodynamic data from a completed Phase 1 single ascending dose study in healthy volunteers, supporting EGL-003's advancement to a multiple ascending dose trial in atopic dermatitis.
Dr. Jonathan Back, Autoimmunity Scientific Program Lead, highlights how the Phase 1 IL-2 Treg agonist mobilizes regulatory T cells to restore immune balance in inflamed tissue, including hidradenitis suppurativa.
The EU funding supports an Egle-led consortium running a Phase 1/2 neoadjuvant trial of EGL-001 with pembrolizumab in head and neck squamous cell carcinoma.
EGL-003, a selective IL-2 agonist, was well tolerated across all four dose cohorts. EGL-003 produced selective, dose-dependent Treg expansion without amplification of conventional CD4, CD8...
PARIS, Sept. 30, 2026 (GLOBE NEWSWIRE)-- Egle Therapeutics ("Egle"), a clinical-stage biotechnology company pioneering precision medicines that modulate regulatory T cells (Tregs) to rebalance immune...
ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness. PARIS...
Egle Therapeutics is a pioneer in the field of immunotherapy. This biotechnology company relies on research from the Curie Institute to fight cancer...
Track Egle and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Discover what's making headlines across other trending companies.